3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
17
Myelodysplastic Syndromes
7
Leukemia, Myelomonocytic, Chronic
4
Ovarian Neoplasms
2
Melanoma
2
Leukemia
2
Fallopian Tube Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoma, T-Cell
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Monocytic, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia, Basophilic, Acute
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
pembrolizumab
2
venetoclax
1
taxane
1
sargramostim
1
rucaparib
1
olaparib
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
Platinum
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Observation
1
Nivolumab
1
Monatide (IMS 3015)
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Carboplatin
1
Capecitabine
1
Azacitidine
1
Antimetabolites
1
Anthracyclines
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Pathologic Complete Response
×
Decitabine
×
Clear all
NCT04229979
2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3
Active not recruiting
127 enrolled